PROGRESSION AND SURVIVAL IN PROSTATIC ADENOCARCINOMA - A COMPARISON OF CLINICAL STAGE, GLEASON GRADE, S-PHASE FRACTION AND DNA-PLOIDY

Citation
S. Vesalainen et al., PROGRESSION AND SURVIVAL IN PROSTATIC ADENOCARCINOMA - A COMPARISON OF CLINICAL STAGE, GLEASON GRADE, S-PHASE FRACTION AND DNA-PLOIDY, British Journal of Cancer, 70(2), 1994, pp. 309-314
Citations number
36
Categorie Soggetti
Oncology
Journal title
ISSN journal
00070920
Volume
70
Issue
2
Year of publication
1994
Pages
309 - 314
Database
ISI
SICI code
0007-0920(1994)70:2<309:PASIPA>2.0.ZU;2-C
Abstract
Clinical data were reviewed in 325 patients with prostatic adenocarcin oma followed up for a mean of 13 years. Paraffin-embedded tumour biops y specimens from the primary rumours were available for Bow cytometry (FCM) in 273 cases. Intra-tumour heterogeneity in DNA index (DI) was f ound in 4% of the tumours (54 cases were analysed). S-phase fraction ( SPF) and DNA ploidy were significantly interrelated. Aneuploidy and hi gh SPF were significantly related to both a high T category and high G leason score. The progression in T1-2M0 tumours was related to Gleason score (P=0.009), DNA ploidy (P=0.006) and SPF (P=0.007), while the Gl eason score (P=0.0013), DNA ploidy (P=0.002) and SPF (P<0.001) had pro gnostic value in univariate survival analysis. In the entire cohort, t he T category (P<0.001), M category (P<0.001), Gleason score (P<0.001) , DNA ploidy (P<0.001) and SPF (P<0.001) were significant prognostic f actors. In Cox's analysis, the M category (P<0.001), Gleason score (P< 0.001), T category (P=0.003), age (P=0.001) and SPF (P=0.087) were ind ependently related to prognosis. In the T1-2M0 tumours, Gleason score (P<0.001), T category (P=0.022) and SPF (P=0.058) were independent pre dictors. A novel classification system in which the DNA ploidy or SPF and the Gleason score were combined was found to be of significant pro gnostic value in all MO tumours (P<0.001). The results suggest that FC M can be used as an adjunct to conventional histological assessments f or determination of the correct prognostic category in prostatic adeno carcinoma.